Summary

Prior 24-week Phase 3 clinical trials (randomized, double-blind) established the efficacy of empagliflozin (10 and 25 mg) in reducing systolic BP compared with placebo among patients with type 2 diabetes. This article presented findings of the 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus [EMPA-REG BP; NCT01370005], a placebo-controlled Phase 3 trial (randomized, double-blind).